Understanding the Patient Perception of Statin Experience: A Qualitative Study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
Not applicable
Amgen - International
PubMed
31482507
PubMed Central
PMC6822972
DOI
10.1007/s12325-019-01073-7
PII: 10.1007/s12325-019-01073-7
Knihovny.cz E-zdroje
- Klíčová slova
- Cardiology, Dyslipidemia, Lipid-lowering therapy, Patient experience, Qualitative research, Statin, Survey,
- MeSH
- anticholesteremika škodlivé účinky terapeutické užití MeSH
- bolest chemicky indukované MeSH
- dospělí MeSH
- dyslipidemie farmakoterapie epidemiologie MeSH
- kvalitativní výzkum MeSH
- lidé středního věku MeSH
- lidé MeSH
- průzkumy a dotazníky MeSH
- senioři MeSH
- spokojenost pacientů statistika a číselné údaje MeSH
- statiny škodlivé účinky terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
- Názvy látek
- anticholesteremika MeSH
- statiny MeSH
INTRODUCTION: Statin intolerance (SI) occurs in patients with dyslipidemia treated with statins. Statin-associated symptoms have been reported, but the overall patient experience is poorly understood. No instruments are available to collect this patient experience. Our aim is to develop a patient survey to define SI from the patient's perspective, inform clinical practice, and identify potential patient characteristics and barriers associated with discontinuing treatment when statin-related difficulties are encountered. METHODS: We conducted qualitative concept elicitation interviews with 65 patients across 12 European study sites. A semi-structured qualitative interview guide was developed based on literature review and clinician interviews. Concept elicitation interviews with patients were used to describe the patient experience and develop the conceptual framework for the survey. RESULTS: Symptoms experienced by patients included muscle and non-muscle-related pain and discomfort; other muscle-related symptoms; gastrointestinal, cardiovascular, cold-like, fatigue-related, and sensory and systems symptoms; mood changes; and cognitive and memory problems. Impacts included limitations on general physical functioning; physical activities; social functioning; emotional impacts; sleep disturbances; decreased productivity; and increased healthcare use. Conceptual framework elements to support survey goals include demographic and clinical characteristics, health information and beliefs, statin side-effect history, symptom severity, and impact severity. CONCLUSIONS: Symptoms and impacts described by patients showed a wider range of symptoms and impacts than usually discussed clinically. The patient survey is designed to capture information from patients who experience difficulties with statin therapy and may be useful in identifying patients who are at higher risk for giving up or discontinuing their treatment. FUNDING: Amgen Inc.
Amgen Inc One Amgen Center Drive Thousand Oaks CA USA
Charles University and General University Hospital of Prague Prague Czech Republic
Health Research Associates Inc 6505 216th St SW Suite 105 Mountlake Terrace WA 98043 USA
Zobrazit více v PubMed
Ito MK. Dyslipidemia: management using optimal lipid-lowering therapy. Ann Pharmacother. 2012;46:1368–1381. doi: 10.1345/aph.1R127. PubMed DOI
Health-at-a-glance-2013. Available from: https://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf. Accessed 23 Aug 2019.
Algharably EA, Filler I, Rosenfeld S, Grabowski K, Kreutz R. Statin intolerance—a question of definition. Expert Opin Drug Saf. 2017;16:55–63. doi: 10.1080/14740338.2017.1238898. PubMed DOI
Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36:1012–1022. doi: 10.1093/eurheartj/ehv043. PubMed DOI PMC
Muntean DM, Thompson PD, Catapano AL, et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today. 2017;22:85–96. doi: 10.1016/j.drudis.2016.09.001. PubMed DOI
Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6–15. doi: 10.1016/j.ahj.2014.03.019. PubMed DOI
Vonbank A, Drexel H, Agewall S, et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur Heart J Cardiovasc Pharmacother. 2018;4:230–236. doi: 10.1093/ehjcvp/pvy028. PubMed DOI
Tuccori M, Lapi F, Testi A, et al. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2008;31:1115–1123. doi: 10.2165/0002018-200831120-00007. PubMed DOI
Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603. doi: 10.1016/j.ahj.2013.06.004. PubMed DOI PMC
Kutner JS, Blatchford PJ, Taylor DH, Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175:691–700. doi: 10.1001/jamainternmed.2015.0289. PubMed DOI PMC
Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance. J Atheroscler Thromb. 2019;26:207–215. doi: 10.5551/jat.RV17030. PubMed DOI PMC
Koskinas K, Wilhelm M, Windecker S. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Med Wkly. 2016;146:w14333. PubMed
figshare
10.6084/m9.figshare.9632114
